文献类型：期刊文献

英文题名：Metal complexes against breast cancer stem cells

作者：Li, Yingsi[1];Liu, Boxin[1];Shi, Hongdong[2];Wang, Yi[3];Sun, Qi[1];Zhang, Qianling[2]

机构：[1]Shenzhen Univ, Hlth Sci Ctr, Dept Pharmacol, Guangdong Key Lab Genome Stabil & Dis Prevent,Int, Shenzhen 518060, Guangdong, Peoples R China;[2]Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen 518060, Peoples R China;[3]East China Univ Sci & Technol, Key Lab Adv Mat MOE, Sch Chem & Mol Engn, Shanghai 200031, Peoples R China

年份：2021

卷号：50

期号：41

起止页码：14498

外文期刊名：DALTON TRANSACTIONS

收录：;EI(收录号：20214411104102);WOS:【SCI-EXPANDED(收录号:WOS:000701973000001)】；

基金：This work was supported by the National Natural Science Foundation of China (21877103, 81602344, 21907069, 81802662), the Project of Natural Science Foundation of Guangdong Province (2019A1515011958), SZU Medical Young Scientists Program (Grant No. 71201-000001), Medical Science and Technology Research Foundation of Guangdong Province (Grant No. A2019475) and Collaborative Innovation Center of Suzhou Nano Science and Technology for support.

语种：英文

外文关键词：Tin compounds - Metals - Palladium compounds - Cytology - Pathology - Stem cells - Tumors - Chemotherapy - Disease control - Diseases - Platinum compounds

摘要：With the highest incidence, breast cancer is the leading cause of cancer deaths among women in the world. Tumor metastasis is the major contributor of high mortality in breast cancer, and the existence of cancer stem cells (CSCs) has been proven to be the cause of tumor metastasis. CSCs are a small proportion of tumor cells, and they are associated with self-renewal and tumorigenic potential. Given the significance of CSCs in tumor initiation, expansion, relapse, resistance, and metastasis, studies should investigate and discover effective anticancer agents that can not only inhibit the proliferation of differentiated tumor cells but also reduce the tumorigenic capability of CSCs. Thus, new therapies must be discovered to treat and prevent this severely hazardous disease of human beings. The success of platinum complexes in cancer treatment has laid the basic foundation for the utilization of metal complexes in the treatment of malignant cancers, in particular the highly aggressive triple-negative breast cancer. Importantly, metal complexes currently have diverse and versatile competences in the therapeutic targeting of CSCs. The anti-CSC properties provide a strong impetus for the development of novel metal-based compounds for the targeting of CSCs and treatment of chemotherapy-resistant and relapsed tumors. In this review, we provide the latest advances in metal complexes including platinum, ruthenium, osmium, iridium, manganese, cobalt, nickel, copper, zinc, palladium, and tin complexes against breast CSCs obtained over the past decade, with pertinent literature including those published until 2021.